MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Development of a patient journey map for people living with cervical dystonia

M. Benson, A. Albanese, K. Bhatia, P. Cavillon, L. Cuffe, K. König, C. Reinhard, H. Graessner (Brussels, Belgium)

Meeting: 2022 International Congress

Abstract Number: 557

Keywords: Botulinum toxin: Clinical applications: dystonia, Dystonia: Clinical features, Dystonia: Treatment

Category: Dystonia: Epidemiology, Genetics, Phenomenology

Objective: As part of the ongoing European Reference Networks for Rare Neurological Diseases (ERN-RND) program, we aimed to develop a cervical dystonia patient journey map (CDPJM) that describes the holistic patient experience from pre-diagnosis through to long-term treatment.

Background: Patient experience and satisfaction have been demonstrated to be the single most important aspect in assessing the quality of healthcare. Patient journey maps are increasingly used as a tool that enables healthcare providers to refine their service provision to best meet patient needs.

Method: The CDPJM was developed in 2 stages; a survey of 15 patients with cervical dystonia (CD) informed the design of the CDPJM, which was then refined and validated by an expert-patient focus group.

Results: Qualitative analysis supported 5 stages of the patient journey: symptom onset, diagnosis and therapeutic relationship with healthcare professionals, initiation of CD care, start of treatment, and living with treated CD. Following symptom onset, patients described multiple visits to their family doctor who prescribed pain killers and muscle relaxants, and referred their patient to up to 10 specialists for diagnosis. Over half (53.3%) had received ≥1 misdiagnosis. Patients reported relief upon correct diagnosis but a lack of understanding of the prognosis and treatment options; 46.7% said their neurologist did not spend enough time addressing their concerns. While botulinum toxin (BoNT) was consistently discussed as the main treatment option, some neurologists also mentioned physiotherapy, counselling, and other complementary approaches. However, patients were often left to seek complementary services themselves. Patients reported a ‘rollercoaster’ of relief with BoNT treatment with symptoms (and subsequent impact on daily life) returning towards the end of an injection cycle. “When BoNT works well I can return to an almost normal life … when the injections stop working so well, I have to rest more and avoid going to work and experience life restrictions.”

Conclusion: We present the first patient journey map for CD that can be used to guide local service mapping and to compare current provision with what patients say they want and need.

To cite this abstract in AMA style:

M. Benson, A. Albanese, K. Bhatia, P. Cavillon, L. Cuffe, K. König, C. Reinhard, H. Graessner. Development of a patient journey map for people living with cervical dystonia [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/development-of-a-patient-journey-map-for-people-living-with-cervical-dystonia/. Accessed July 11, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/development-of-a-patient-journey-map-for-people-living-with-cervical-dystonia/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley